RxDoctor Payments Data

Marian Vulpe, MD

Cardiovascular Disease · Hamden, CTNPI 1013907476

Payments from drug & device makers

$14,582in general payments, 2019–2025

Across 791 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Novartis$937
  • Merck$930
  • Amgen$914
  • plus $7K from 36 others

What the payments were for

  • Food & beverage$14,46199%
  • Education$1211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,582 in reported general payments places this provider in the 80th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$561,253
Medicare patients
781
Services billed
5,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban256$332,276
EntrestoSacubitril/Valsartan164$263,018
XareltoRivaroxaban74$103,787
Repatha SureclickEvolocumab92$97,986
OzempicSemaglutide56$70,833
FarxigaDapagliflozin Propanediol46$49,925
NexlizetBempedoic Acid/Ezetimibe46$42,555
JardianceEmpagliflozin26$35,885
EdarbiAzilsartan Medoxomil53$31,574
Ranolazine ErRanolazine83$23,806
EdarbyclorAzilsartan Med/Chlorthalidone46$23,417
BrilintaTicagrelor25$23,386
Repatha SyringeEvolocumab17$22,521
Praluent PenAlirocumab16$22,014
VascepaIcosapent Ethyl18$17,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$572$332,276256 claims
NovartisEntresto$937$263,018164 claims
Johnson & JohnsonXarelto$717$103,78774 claims
Novo NordiskOzempic, Wegovy$1,904$88,51269 claims
AstraZenecaFarxiga, Brilinta$1,306$73,31071 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$573$54,99099 claims
Esperion Therapeutics, Inc.Nexlizet$310$42,55546 claims
Boehringer IngelheimJardiance$554$35,88526 claims
Kowa Pharmaceuticals America, Inc.Livalo$400$11,76012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Hamden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →